Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP
- PMID: 18673173
- DOI: 10.2174/156802608784911626
Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP
Abstract
Kinesin spindle protein (KSP), a mitotic kinesin responsible for bipolar spindle establishment and maintenance, is currently the target of intense research for the development of novel anticancer therapeutics. Several inhibitors of KSP have progressed into clinical trials and many others are in preclinical development. A majority of these inhibitors are ATP-uncompetitive and bind in an allosteric loop L5 binding pocket, but recently, inhibitors with an alternative mechanism of action (ATP-competitive) have also been identified and characterized. In this review, an update of the clinical trial results with ATP-uncompetitive KSP inhibitors is provided and recent progress in the identification of additional KSP inhibitors is discussed.
Similar articles
-
Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds.Curr Med Chem. 2014;21(23):2691-701. doi: 10.2174/0929867321666140304110609. Curr Med Chem. 2014. PMID: 24606497 Review.
-
Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.J Biomol Struct Dyn. 2018 Nov;36(14):3687-3704. doi: 10.1080/07391102.2017.1396255. Epub 2017 Nov 29. J Biomol Struct Dyn. 2018. PMID: 29064326
-
Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present).Expert Opin Ther Pat. 2013 Dec;23(12):1547-60. doi: 10.1517/13543776.2013.833606. Epub 2013 Aug 26. Expert Opin Ther Pat. 2013. PMID: 23978071 Review.
-
Novel ATP-competitive kinesin spindle protein inhibitors.J Med Chem. 2007 Oct 4;50(20):4939-52. doi: 10.1021/jm070435y. Epub 2007 Aug 29. J Med Chem. 2007. PMID: 17725339
-
Progress on kinesin spindle protein inhibitors as anti-cancer agents.Anticancer Agents Med Chem. 2008 Aug;8(6):698-704. Anticancer Agents Med Chem. 2008. PMID: 18690830 Review.
Cited by
-
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.Bioorg Med Chem. 2011 Sep 15;19(18):5446-53. doi: 10.1016/j.bmc.2011.07.054. Epub 2011 Jul 30. Bioorg Med Chem. 2011. PMID: 21855351 Free PMC article.
-
Discovery of a novel inhibitor of kinesin-like protein KIFC1.Biochem J. 2016 Apr 15;473(8):1027-35. doi: 10.1042/BJ20150992. Epub 2016 Feb 4. Biochem J. 2016. PMID: 26846349 Free PMC article.
-
Analysis of Biphenyl-Type Inhibitors Targeting the Eg5 α4/α6 Allosteric Pocket.ACS Omega. 2017 May 31;2(5):1836-1849. doi: 10.1021/acsomega.6b00467. Epub 2017 May 5. ACS Omega. 2017. PMID: 30023646 Free PMC article.
-
Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells.Biol Res. 2014 Dec 15;47(1):70. doi: 10.1186/0717-6287-47-70. Biol Res. 2014. PMID: 25723613 Free PMC article.
-
Focus on Extracellular Vesicles: Development of Extracellular Vesicle-Based Therapeutic Systems.Int J Mol Sci. 2016 Feb 6;17(2):172. doi: 10.3390/ijms17020172. Int J Mol Sci. 2016. PMID: 26861303 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources